Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Fate Therapeutics Inc.

    NASDAQ: FATE · Real-Time Price · USD
    1.23
    -0.04 (-3.53%)
    At close: Jun 16, 2025, 3:59 PM
    1.24
    0.81%
    Pre-market: Jun 17, 2025, 08:04 AM EDT

    Fate Therapeutics Statistics

    Share Statistics

    Fate Therapeutics has 114.63M shares outstanding. The number of shares has increased by 0.67% in one year.

    Shares Outstanding

    n/a
    		 114.63M

    Shares Change (YoY)

    n/a
    		 0.67%

    Shares Change (QoQ)

    n/a
    		 0.62%

    Owned by Institutions (%)

    n/a
    		 86.24%

    Shares Floating

    n/a
    		 107.09M

    Failed to Deliver (FTD) Shares

    n/a
    		 61,661

    FTD / Avg. Volume

    n/a
    		 3.02%

    Short Selling Information

    The latest short interest is 11.05M, so 9.64% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 11.05M

    Short % of Shares Out

    n/a
    		 9.64%

    Short % of Float

    n/a
    		 11%

    Short Ratio (days to cover)

    n/a
    		 6.99

    Valuation Ratios

    The PE ratio is -1.01 and the forward PE ratio is -1.06. Fate Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -1.01

    Forward PE

    n/a
    		 -1.06

    PS Ratio

    n/a
    		 13.76

    Forward PS

    n/a
    		 3.6

    PB Ratio

    n/a
    		 0.59

    P/FCF Ratio

    n/a
    		 -1.52

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Fate Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 7.58, with a Debt / Equity ratio of 0.27.

    Current Ratio

    n/a
    		 7.58

    Quick Ratio

    n/a
    		 7.58

    Debt / Equity

    n/a
    		 0.27

    Debt / EBITDA

    n/a
    		 -0.48

    Debt / FCF

    n/a
    		 -0.69

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $75,309.39

    Profits Per Employee

    n/a
    		 $-1,029,071.82

    Employee Count

    n/a
    		 181

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -65.55% in the last 52 weeks. The beta is 2.23, so Fate Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.23

    52-Week Price Change

    n/a
    		 -65.55%

    50-Day Moving Average

    n/a
    		 1.19

    200-Day Moving Average

    n/a
    		 1.9

    Relative Strength Index (RSI)

    n/a
    		 47.42

    Average Volume (20 Days)

    n/a
    		 2,043,201

    Income Statement

    In the last 12 months, Fate Therapeutics had revenue of 13.63M and earned -186.26M in profits. Earnings per share was -1.64.

    Revenue

    n/a
    		 13.63M

    Gross Profit

    n/a
    		 13.63M

    Operating Income

    n/a
    		 -210.28M

    Net Income

    n/a
    		 -186.26M

    EBITDA

    n/a
    		 -176.58M

    EBIT

    n/a
    		 -195.54M

    Earnings Per Share (EPS)

    n/a
    		 -1.64
    Full Income Statement

    Balance Sheet

    The company has 36.06M in cash and 85.27M in debt, giving a net cash position of -49.21M.

    Cash & Cash Equivalents

    n/a
    		 36.06M

    Total Debt

    n/a
    		 85.27M

    Net Cash

    n/a
    		 -49.21M

    Retained Earnings

    n/a
    		 -1.4B

    Total Assets

    n/a
    		 398.67M

    Working Capital

    n/a
    		 220.06M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -122.87M and capital expenditures -730K, giving a free cash flow of -123.6M.

    Operating Cash Flow

    n/a
    		 -122.87M

    Capital Expenditures

    n/a
    		 -730K

    Free Cash Flow

    n/a
    		 -123.6M

    FCF Per Share

    n/a
    		 -1.09
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -1542.63% and -1366.46%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -1542.63%

    Pretax Margin

    n/a
    		 -1366.46%

    Profit Margin

    n/a
    		 -1366.46%

    EBITDA Margin

    n/a
    		 -1295.41%

    EBIT Margin

    n/a
    		 -1542.63%

    FCF Margin

    n/a
    		 -906.79%

    Dividends & Yields

    FATE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for FATE is $4, which is 225.2% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 225.2%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 8
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -5.09

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist